Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone.

International journal of antimicrobial agents - 1 Apr 2015

Gopal Pooja, Dick Thomas

Abstract excerpt

Perchlozone(®) (PCZ), a new thiosemicarbazone developed by JSC Pharmasyntez (Moscow, Russia) for the treatment of tuberculosis (TB), was approved for use against multidrug-resistant disease in Russia in 2012. The mechanism of action of the drug is unknown. A well-studied thiosemicarbazone is the old TB drug thiacetazone (TAC). It has a narrow spectrum and inhibits the FASII dehydratase complex HadABC, which is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Drug Resistance, Bacterial
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mycobacterium tuberculosis

Share to Oxidoreductases

Source

Identifiers

PMID: 25704063
DOI: 10.1016/j.ijantimicag.2014.12.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone.PMID 25704063Read ↗

Perсhlozone Resistance in Clinical Isolates of Mycobacterium tuberculosisSemantic proximity Read ↗

Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues.Semantic proximity Read ↗

Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384.Semantic proximity Read ↗

A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone.Semantic proximity Read ↗

NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs In Vitro and In VivoSemantic proximity Read ↗

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.Semantic proximity Read ↗

New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis.Semantic proximity Read ↗

Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in MycobacteriaSemantic proximity Read ↗

Mutations in the essential FAS II β-hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii.Semantic proximity Read ↗

Side Chain-modified Benzothiazinone Derivatives with Anti-Mycobacterial ActivitySemantic proximity Read ↗

In vitro antimycobacterial activity of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione: a new chemical entity against Mycobacterium tuberculosis.Semantic proximity Read ↗

New structural classes of antituberculosis agentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.